Trials / Completed
CompletedNCT05214690
A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809-T2
A Phase 1 Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics After Administration of DW1809-T2 and DW1809-1 in Healthy Adult Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Daewon Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Accepted
Summary
Randomized, Open-label, Oral, Single-dose, two-Sequence, four-Period, crossover study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DW1809-T2 | pelubiprofen 25mg |
| DRUG | DW1809-1 | pelubiprofen 30mg (PELUBI tab.) |
Timeline
- Start date
- 2020-08-13
- Primary completion
- 2020-09-08
- Completion
- 2020-09-08
- First posted
- 2022-01-31
- Last updated
- 2022-01-31
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05214690. Inclusion in this directory is not an endorsement.